Effect of genetic polymorphisms on smoking cessation: A trial of bupropion in Korean male smokers

Psychiatric Genetics

Volumn 18, Issue 1, 2008, Pages 11-16

  Han, Doug Hyun ^a   Joe, Keun Ho ^b   Na, Chul ^c   Lee, Young Sik ^c  

^a MCLEAN HOSPITAL   (United States)

^b Department of Psychiatry   (South Korea)

^c Chung Ang University   (South Korea)

Author keywords

Abstinence rate; Bupropion; Genetic polymorphism; Nicotine dependence; Smoking cessation

Indexed keywords

AMFEBUTAMONE; CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; NICOTINE; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER;

ARTICLE; DNA EXTRACTION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; KOREA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SMOKING CESSATION; TREATMENT OUTCOME;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BUPROPION; DEMOGRAPHY; GENE FREQUENCY; GENOTYPE; HUMANS; KOREA; MALE; POLYMORPHISM, GENETIC; SMOKING CESSATION; TREATMENT FAILURE;

EID: 38149092648     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/YPG.0b013e3282df0939     Document Type: Article

References (29)

1. Comings D, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D (1996). The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 6:73-79.
2. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM (1994). Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11:133-141.
3. David SP, Niaura R, Papandonatos GD, Shadel WG, Burkholder GJ, Britt DM, et al. (2002a). Does the DRD2-TaqIA polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res 5:935-942.
4. David SP, Johnstone E, Griffiths SE, Murphy M, Yudkin P, Mant D, et al. (2002b). No association between functional catechol-O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics 12:265-268.
5. Durcan MJ, Deener G, White J, Johnson JA, Gonzales D, Niaura R, et al. (2002). The effects of bupropion sustained-release on cigarette craving after smoking cessation. Clin Ther 24:540-551.
6. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al. (2000). Treating tobacco use and dependence. Clinical Practice Guideline. Rockville, Madison: US Department of Health and Human Services, Public Health Service.
7. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S (2001). The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 1:152-156.
8. Goldman D, Brown GL, Albaugh B, Robin R, Goodson S, Trunzo M, et al. (1993). DRD2 dopamine receptor genotype, linkage disequilibrium, and alcoholism in American Indians and other populations. Alcohol Clin Exp Res 17:199-204.
9. Heatherton T, Kozlowski L, Frecker R, Fagerstrom K (1991). The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119-1127.
10. Holm KJ, Spencer CM (2000). Bupropion: a review of its use in the management of smoking cessation. Drugs 59:1007-1024.
11. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE (2003). Measure of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 5:13-25.
12. Hurt R, Sachs D, Glover E, Offord K, Johnston J, Dale L, et al. (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1202.
13. Hutchison KE, LaChance H, Niaura R, Bryan A, Smolen A (2002). The DRD4 VNTR polymorphism influences reactivity to smoking cues. J Abnorm Psychol 111:134-143.
14. Ishikawa H, Ohtsuki T, Ishiguro H, Yamakawa-Kobayashi K, Endo K, Lin YL, et al. (1999). Association between serotonin transporter gene polymorphism and smoking among Japanese males. Cancer Epidemiol Biomarkers Prev 8:831-833.
15. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243-250.
16. Lawford BR, Young RM, Rowell JA, Qualichefski J, Fletcher BH, Syndulko K, et al. (1995). Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med 1:337-341.
17. Lee HS (2003). Gender-specific molecular heterosis and association studies: dopamine D2 receptor gene and smoking. Am J Med Genet 118:55-59.
18. Lerman C, Roth D, Kaufman V, Audrain J, Main D, Browman ED, et al. (1999). Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18:14-20.
19. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, et al. (2003). Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22:541-548.
20. Little KY, McLaughlin DP, Zhang L, Livermore CS, Dalack GW, McFinton PR, et al. (1998). Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Psychiatry 155:207-213.
21. McKinney EF, Walton RT, Yudkin P, Fuller A, Haldar NA, Mant D, et al. (2000). Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 10:483-491.
22. Nakatome M, Honda K, Tun Z, Wakasugi C (1996). Detection and analysis of the human D4 dopamine receptor gene (DRD4) sequence variant in the Japanese and Mongolian population. Biochem Biophys Res Commun 220:773-776.
23. Palmatier MA, Kang AM, Kidd KK (1999). Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol Psychiatry 46:557-567.
24. Ritchie T, Noble EP (2003). Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 28:73-82.
25. Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, Hu S, et al. (1999). A genetic association for cigarette smoking behavior. Health Psychol 18:7-13.
26. Samochowiec J, Kucharska-Mazur J, Kaminski R, Smolka M, Rommelschpacherc H, Wernickec C, et al. (2002). Norepinephrine transporter gene polymorphism is not associated with susceptibility to alcohol dependence. Psychiatry Res 111:229-233.
27. Sanchez C, Hyttel J (1999). Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467-489.
28. Shiffman S, Johnson JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, et al. (2000). The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 148:33-40.
29. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM (1997). High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abuses. Am J Med Genet 74:439-442.